Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm...
Pharmaceutical
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition,...
VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
Vanqua Bio to Present at the Stifel 2023 CNS Day Conference
CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company focused on discovering and developing next-generation medicines that...
Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset Development
Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial ExecutionMORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos...
InflaRx Reports Full Year 2022 Financial and Operating Results
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback and recommendations from the U.S....
Medexus Announces New License Deal for Topical Terbinafine
TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that the company...
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company...
Wesana Health Announces Sale of SANA-13 Assets to Lucy Scientific Discovery
CHICAGO and TORONTO, March 21, 2023 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),...
H1 Expands HCP Universe to Help Medical Affairs Understand and Track the Impact of Their Activities, Drive Adherence to Evidence-based Medicine, and Improve Patient Outcomes
New features provide real-time updates on the impact medical affairs teams are having on the HCP and HCO community to...
Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder
The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., March 21, 2023 (GLOBE NEWSWIRE) --...
Lucy Scientific to Acquire SANA-013 Psychedelic Assets from Drug Developer Wesana Health
Transaction subject to Wesana shareholder approval and expected to close in Q2 2023SANA-013 combination of psilocybin and CBD being developed for potential...
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain...
Cerevance Announces Presentations at Two Medicinal Chemistry Conferences
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today...
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Dupixent®(dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More...
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks...
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to...
HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress
BOSTON, March 17, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Big Sky, Montana
MINNEAPOLIS, MN, US, March 17, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or “PetVivo")...